A Phase Ib Study Evaluating the Safety and Tolerability of Durvalumab (MEDI4736) (Anti-PDL1) in Combination With Eribulin in Patients With HER2-Negative Metastatic Breast Cancer and Recurrent Ovarian Cancer
Phase of Trial: Phase I
Latest Information Update: 05 Jun 2018
At a glance
- Drugs Durvalumab (Primary) ; Eribulin (Primary)
- Indications Advanced breast cancer; Male breast cancer; Ovarian cancer
- Focus Adverse reactions
- 05 Jun 2018 Trial design presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
- 18 May 2018 Status changed from not yet recruiting to recruiting.
- 03 May 2018 Planned initiation date changed from 12 Feb 2018 to 14 May 2018.